Behandling med dopaminagonister og udvikling af hjerteklapsygdom hos patienter med hyperprolaktinæmi

Charlotte Steffensen; Merete Lund Mægbæk; Peter Laurberg; Marianne Andersen; Caroline Kistorp; Helene Nørrelund; Jakob Dal; Jens Otto Lunde Jørgensen

Behandling med dopaminagonister og udvikling af hjerteklapsygdom hos patienter med hyperprolaktinæmi

Translated title of the contribution: Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients

Charlotte Steffensen, Merete Lund Mægbæk, Peter Laurberg, Marianne Andersen, Caroline Kistorp, Helene Nørrelund, Jakob Dal, Jens Otto Lunde Jørgensen

Department of Clinical Medicine

Abstract

Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patientsTreatment with dopamin agonists, particularly cabergoline, is the primary and preferred therapy for prolactinomas and symptomatic hyperprolactinaemia due to its effectiveness and tolerability. However, an association has been demonstrated between fibrotic heart valve disease and high-dose dopamin agonist use in patients with Parkinson's disease in several echocardiographic studies. Such observations have prompted a number of studies of valvular function in cabergoline-treated hyperprolactinaemia patients. These studies have failed to show an increased prevalence of clinically significant valvular regurgitation.

Translated title of the contribution	Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients
Original language	Danish
Journal	Ugeskrift for Laeger
Volume	176
Issue number	1
Pages (from-to)	58-60
Number of pages	3
ISSN	0041-5782
Publication status	Published - 6 Jan 2014

Cite this

@article{8d7531a9a57046149d006bda0c71c772,

title = "Behandling med dopaminagonister og udvikling af hjerteklapsygdom hos patienter med hyperprolaktin{\ae}mi",

abstract = "Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patientsTreatment with dopamin agonists, particularly cabergoline, is the primary and preferred therapy for prolactinomas and symptomatic hyperprolactinaemia due to its effectiveness and tolerability. However, an association has been demonstrated between fibrotic heart valve disease and high-dose dopamin agonist use in patients with Parkinson's disease in several echocardiographic studies. Such observations have prompted a number of studies of valvular function in cabergoline-treated hyperprolactinaemia patients. These studies have failed to show an increased prevalence of clinically significant valvular regurgitation.",

author = "Charlotte Steffensen and M{\ae}gb{\ae}k, {Merete Lund} and Peter Laurberg and Marianne Andersen and Caroline Kistorp and Helene N{\o}rrelund and Jakob Dal and J{\o}rgensen, {Jens Otto Lunde}",

year = "2014",

month = jan,

day = "6",

language = "Dansk",

volume = "176",

pages = "58--60",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "1",

}

TY - JOUR

T1 - Behandling med dopaminagonister og udvikling af hjerteklapsygdom hos patienter med hyperprolaktinæmi

AU - Steffensen, Charlotte

AU - Mægbæk, Merete Lund

AU - Laurberg, Peter

AU - Andersen, Marianne

AU - Kistorp, Caroline

AU - Nørrelund, Helene

AU - Dal, Jakob

AU - Jørgensen, Jens Otto Lunde

PY - 2014/1/6

Y1 - 2014/1/6

N2 - Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patientsTreatment with dopamin agonists, particularly cabergoline, is the primary and preferred therapy for prolactinomas and symptomatic hyperprolactinaemia due to its effectiveness and tolerability. However, an association has been demonstrated between fibrotic heart valve disease and high-dose dopamin agonist use in patients with Parkinson's disease in several echocardiographic studies. Such observations have prompted a number of studies of valvular function in cabergoline-treated hyperprolactinaemia patients. These studies have failed to show an increased prevalence of clinically significant valvular regurgitation.

AB - Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patientsTreatment with dopamin agonists, particularly cabergoline, is the primary and preferred therapy for prolactinomas and symptomatic hyperprolactinaemia due to its effectiveness and tolerability. However, an association has been demonstrated between fibrotic heart valve disease and high-dose dopamin agonist use in patients with Parkinson's disease in several echocardiographic studies. Such observations have prompted a number of studies of valvular function in cabergoline-treated hyperprolactinaemia patients. These studies have failed to show an increased prevalence of clinically significant valvular regurgitation.

M3 - Tidsskriftartikel

C2 - 24629610

SN - 0041-5782

VL - 176

SP - 58

EP - 60

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 1

ER -

Behandling med dopaminagonister og udvikling af hjerteklapsygdom hos patienter med hyperprolaktinæmi

Abstract

Fingerprint

Cite this